Repotrectinib

Overview

Repotrectinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4298138).

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Repotrectinib expires 24 Jul 2036 and exclusivity 13 Jun 2031. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

(3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one

Canonical SMILES

C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@@H](C4=C(O1)C=CC(=C4)F)C

InChIKey

FIKPXCOQUIZNHB-WDEREUQCSA-N